Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 18 October 2012
Chronic regulatory lapses at manufacturing facilities are exacerbating drug shortages and patient safety issues, claims a new report published in The New York Times.
The report chronicles the huge number of issues-some of them particularly egregious-that have occurred in recent years at facilities responsible for manufacturing pharmaceutical products. The problem is especially prominent at facilities that manufacture sterile injectable drugs, which have experienced widespread shortages in the last two years.
It's easy to see why those shortages have occurred, explained The Times. "In the last three years, six of the major manufacturers of sterile injectable drugs … have been warned by the Food and Drug Administration (FDA) about serious violations of manufacturing rules."
Four of those facilities have closed or reduced their production capacities, leading to widespread shortages for some essential injectable anti-cancer drugs like Doxil.
But the problems go far beyond just injectables. As noted by The Times and a congressional report, "Nearly a third of the industry's manufacturing capacity is off line because of quality issues."
The problems vary depending on the facility, said experts consulted in the article. Some of the factories are old and in need of repair. Others-generic manufacturers, mostly-don't have the funding to make required upgrades to their facilities due to low profit margins. Some just don't have good quality manufacturing plans in place or are short-staffed due to layoffs.
But the problems have been far from minor. Barrels of human urine, rusty tools used in manufacturing and insects in manufacturing areas have all been found at facilities in the last three years. Worse, FDA inspectors have found products contaminated with mold, fungus, bacteria, human hair and insects-all of which could cause severe adverse events or death.
While some facilities are scrambling to upgrade their facilities in the wake of FDA's crackdown on poor manufacturing practices, the costs are tremendous and the timeline long. Ohio-based Ben Vanue, whose facility was suspended after FDA found significant violations of current good manufacturing practices (cGMP), has invested hundreds of millions of dollars to bring its facility up to standards, but the entire process could take as long as five years.
In the meantime, shortages are likely to persist, which could pose a different set of problems. Such shortages have been associated with the rise of compounding pharmacies, which have been used to fill gaps left by more established manufacturers. Those facilities, however, are not as tightly regulated by FDA, and one-Massachusetts-based New England Compounding Center-has been blamed for a massive outbreak of meningitis that has sickened hundreds and killed 19 patients injected with one of its products. In working to fix one problem, critics argue, FDA may have inadvertently caused even worse ones.
Read more:
Tags: warning letter, Contamination, Shortages, Latest News, cGMP, Inspection, regulatory
Regulatory Focus newsletters
All the biggest regulatory news and happenings.